Chinese developers of immune checkpoint inhibitors including PD-1/L1 antibodies are making fresh progress in clinical trials that could pave the way for eventual US regulatory nods in the space of relatively rare small cell lung cancer.
The latest developments seem to add new momentum into Chinese-made checkpoint inhibitors in the wake of prior setbacks, including those encountered by Innovent Biologics, Inc.’s Tyvyt (sintilimab) and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?